# STEREO-RE-PRO (NCT03438552)

> Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03438552
- Phase: NA
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: UNICANCER
- Conditions: Local Recurrence of Malignant Tumor of Prostate
- Interventions: Stereotactic Body Radiotherapy
- Enrollment: 57
- Primary outcome: Selection of the recommended dose for salvage-SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy) based on dose-limiting toxicity observed during the 18 weeks following the initiation of salvage-SBRT.
- Primary outcome: Estimate the efficacy of the salvage-SBRT in terms of biochemical relapse-free survival rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=stereo-re-pro-nct03438552